Pliant Therapeutics, Inc.

Stage 4 · Declining · week 22

As of Oct 22, 2026, Pliant Therapeutics is in Stage 4, the downtrend phase, now in week 22 (since May 19, 2026). It closed at $0.87, 52.2% below its 52-week high and below its 200-day average, which is falling.

Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. More about the company

$0.87

-1.70% today

$53.6M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is PLRX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 19w

S4 23w

S4 26w

S4 22w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 19w → S1 10w → S4 23w → S1 6w → S4 3w → S1 5w → S2 6w → S3 3w → S4 26w → S1 10w → S4 2w → S1 4w → S3 5w → S4 10w → S1 9w → S4 22w current

Total tracked: 164 weeks across 16 stage runs.

PLRX among Biotechnology363rd of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…363	PLRXPliant Therapeutics, Inc.	Stage 4 · wk 22	22	−23.1%

vs 52W High

-52.2%

$0.87 lo$1.81 hi

52.2% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 22

1w13w26w

Week 22, extended decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-26.4%

200 DMA: $1.18 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.67x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-23.1%

-20.6%

-31.3%

YTD

-30.8%

-53.7%

Scan Membership

Breakout Watch

Latest: 2024-12-03

4 appearances in last 60 days. First seen: 2021-03-18.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 22 · Vol 0.67x

2026-10-21S4

Wk 22 · Vol 0.78x

2026-10-20S4

Wk 22 · Vol 0.75x

2026-10-19S4

Wk 22 · Vol 0.68x

2026-10-16S4

Wk 21 · Vol 1.36x

2026-10-15S4

Wk 21 · Vol 1.14x

2026-10-14S4

Wk 21 · Vol 2.43x

2026-10-13S4

Wk 21 · Vol 0.70x

2026-10-12S4

Wk 21 · Vol 0.67x

2026-10-09S4

Wk 20 · Vol 0.71x

2026-10-08S4

Wk 20 · Vol 1.43x

2026-10-07S4

Wk 20 · Vol 1.95x

Moving averages & range

50 DMA

$1.07

200 DMA

$1.18

52W High

$1.81

52W Low

$0.87

5D Low

$0.87

Resistance levels (recent highs)

20d High

$1.08

60d High

$1.19

120d High

$1.26

250d High

$1.81

Next resistance

+24.9%

to 20d High

ROE

-50.3%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.4

Pliant Therapeutics: quick answers

What stage is Pliant Therapeutics in?

As of Oct 22, 2026, Pliant Therapeutics (PLRX) is in Stage 4, the downtrend phase. It entered Stage 4 on May 19, 2026 and is in week 22. What the four stages mean

Is Pliant Therapeutics in an uptrend?

No. Pliant Therapeutics is in a Stage 4 downtrend. It trades 26.4% below its 200-day average, which is falling.

How far is Pliant Therapeutics from its 52-week high?

Pliant Therapeutics closed at $0.87 on Oct 22, 2026, 52.2% below its 52-week high of $1.81. Its 52-week low is $0.87.

How has Pliant Therapeutics performed over the past year?

As of Oct 22, 2026, Pliant Therapeutics is down 53.7% over the past year and down 30.8% so far in 2026.

Which sector and industry is Pliant Therapeutics in?

Pliant Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.